ArticleScience (New York, N.Y.)2013
Immunology. An interferon paradox.
Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.PLoS pathogens · 2013Trial
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance.Frontiers in cellular and infection microbiology · 2026Review
- Early classical swine fever virus persistence is associated with cytotoxic and immunoregulatory transcriptional signatures distinct from protective C-strain vaccination.Frontiers in cellular and infection microbiology · 2026Article
- An activatingScience immunology · 2025Article
- SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes.Annals of medicine · 2023Review
- CD8Immunity · 2023Review
- Type I interferon signaling and macrophages: a double-edged sword?Cellular & molecular immunology · 2022Article
- Is IFN expression by NK cells a hallmark of severe COVID-19?Cytokine · 2022Article
- IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health.JCI insight · 2022Article
- Understanding the Immune System in Fetal Protection and Maternal Infections during Pregnancy.Journal of immunology research · 2022Review
- Anti-type I interferon antibodies as a cause of severe COVID-19.Faculty reviews · 2022Article
- Low-dose exposure to PBDE disrupts genomic integrity and innate immunity in mammary tissue.Frontiers in genetics · 2022Article
- Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.PLoS pathogens · 2021Article
- ISG15 protects human Tregs from interferon alpha-induced contraction in a cell-intrinsic fashion.Clinical & translational immunology · 2020Article
- Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8Journal of virology · 2019Article
- Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents.Immunology and cell biology · 2018Article
- Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.Immunological reviews · 2018Review
- A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.AIDS (London, England) · 2018Article
- Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Oncotarget · 2017Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.